American Cancer Society, Cancer Statistics Center. Kidney and renal pelvis: at a glance. https://cancerstatisticscenter.cancer.org/#!/. Accessed June 6, 2018.
Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14:141-148.
NCCN Guidelines®. Kidney cancer. V2.2018. www.nccn.org. Accessed June 6, 2018.
Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277-1290.
Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomized, phase 2, open label, multicenter trial. Lancet Oncol. 2015;16:1473-1482.
Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa 2a for the treatment of metastatic renal cell carcinoma: a randomized, double blind phase 3 trial. Lancet. 2007;370:2103-2111.
Motzer R, Powles T, Atkins M, et al. IMmotion151: a randomized phase 3 study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic RCC. Oral presentation at: 2018 Genitourinary Cancers Symposium; February 8-10, 2018; San Francisco, CA. Abstract 578.
Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Oral presentation at: European Society for Medical Oncology World Congress on Gastrointestinal Cancer 2018; June 20-23, 2018; Barcelona, Spain. Abstract LBA5.
Lee C, Makker V, Rasco D, et al. A phase 1b/2 trial of lenvatinib + pembrolizumab in patients with renal cell carcinoma. Presented at: European Society for Medical Oncology World Congress on Gastrointestinal Cancer 2018; June 20-23, 2018; Barcelona, Spain. Abstract 8470.
Tecentriq® [package insert]. South San Francisco, CA: Genentech, Inc; 2018.
Opdivo® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2018
Keytruda® [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2017.
Bavencio® [package insert]. New York, NY: EMD Serono, Inc/Pfizer Inc; 2017.
Imfinzi® [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.
Bayne CE, Farah D, Herbst KW, et al. Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis. World J Urol. 2018. [Epub ahead of print]
NCCN Guidelines®. Bladder cancer. Version 3.2018. http://www.NCCN.org. Published March 14, 2018. Accessed May 2, 2018.
Bellmunt J, de Wit R, Vaughn DJ, et al. Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer. Oral presentation at: 2018 Genitourinary Cancers Symposium; February 8-10, 2018; San Francisco, CA. Abstract 410.
Ornstein MC, Grivas P. Selecting and sequencing therapy in advanced urothelial carcinoma: navigating a dynamic landscape. J Target Ther Cancer. 2018. http://www.targetedonc.com/publications/targeted-therapies-cancer/2018/2018-february/selecting-and-sequencing-therapy-in-advanced-urothelial-carcinoma-navigating-a-dynamic-landscape?p=2. Accessed June 6, 2018.
ClinicalTrials.gov. A study of avelumab in patients with locally advanced or metastatic urothelial cancer (JAVELIN Bladder 100). https://clinicaltrials.gov/ct2/show/NCT02603432. Accessed June 6, 2018.
ClinicalTrials.gov. Safety and pharmacology study of atezolizumab alone and in combination with bacillus Calmette-Guérin (BCG) in high-risk non-muscle-invasive bladder cancer (NMIBC) participants. https://clinicaltrials.gov/ct2/show/NCT02792192. Accessed June 6, 2018.
ClinicalTrials.gov. Study of pembrolizumab (MK-3475) in participants with high risk non-muscle Invasive bladder cancer (MK-3475-057/KEYNOTE-057). https://clinicaltrials.gov/ct2/show/NCT02625961. Accessed June 6, 2018.
Galsky MD, Powles T, Li S, et al. A phase III, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) versus SoC alone in patients with previously untreated unresectable or metastatic urothelial carcinoma (CheckMate 901). Poster presented at: 2018 Genitourinary Cancers Symposium; February 8-10, 2018; San Francisco, CA. Poster TPS539.
Drakaki A, Kirby CJ, van der Heijden M, et al. Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): prespecified subgroup analysis from the phase 3 RANGE trial. Poster presented at: 2018 Genitourinary Cancers Symposium; February 8-10, 2018; San Francisco, CA. Abstract 434.
ClinicalTrials.gov. A study of enfortumab vedotin for patients with locally advanced or metastatic urothelial bladder cancer (EV-201). https://clinicaltrials.gov/ct2/show/NCT03219333. Accessed May 3, 2018.
Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015-1026.
National Institutes of Health, National Cancer Institute, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Published November 27, 2017. Accessed May 1, 2018.
Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95.
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Sally Rafikh, RN, BSN, OCN

Clinical Nurse
GU Medical Oncology
Memorial Sloan Kettering Cancer Center
New York, New York

Disclosures

Disclosure: Sally Rafikh, RN, BSN, OCN, has disclosed no relevant financial relationships.

Ms Rafikh does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Rafikh does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

Pam Profusek, RN, MS

GU Research Nurse Coordinator
Taussig Cancer Center
Cleveland Clinic
Cleveland, Ohio

Disclosures

Disclosure: Pam Profusek, RN, MS, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Genentech, Inc.

Ms Profusek does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Profusek does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Virginia Seery, RN, MSN, ANP-BC

Nurse Practitioner
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Disclosures

Disclosure: Virginia Seery, RN, MSN, ANP-BC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Array BioPharma

Ms Seery does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Seery does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Davecia R. Cameron, MS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

CE Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

CE

Oncology Nurse View: Immune Checkpoint Inhibitors in Genitourinary Cancers

Authors:

Sally Rafikh, RN, BSN, OCN; Pam Profusek, RN, MS; Virginia Seery, RN, MSN, ANP-BC

CE Released: 6/24/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 6/24/2019, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for oncology nurses.

The goal of this activity is to provide oncology nurses with the latest information on immunotherapy in genitourinary cancers, including strategies for counseling patients and caregivers about immunotherapy.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Efficacy and safety of immune checkpoint inhibitors in advanced renal cell carcinoma (RCC) and bladder cancer
Have greater competence related to
- Mitigating the adverse events related to treatments for advanced RCC and bladder cancer
- Counseling patients regarding differentiation of adverse events related to immunotherapy vs traditional cancer therapies

Disclosures

Moderator

Sally Rafikh, RN, BSN, OCN

Clinical Nurse
GU Medical Oncology
Memorial Sloan Kettering Cancer Center
New York, New York

Disclosures

Disclosure: Sally Rafikh, RN, BSN, OCN, has disclosed no relevant financial relationships.

Ms Rafikh does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Rafikh does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

Pam Profusek, RN, MS

GU Research Nurse Coordinator
Taussig Cancer Center
Cleveland Clinic
Cleveland, Ohio

Disclosures

Disclosure: Pam Profusek, RN, MS, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Genentech, Inc.

Ms Profusek does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Profusek does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Virginia Seery, RN, MSN, ANP-BC

Nurse Practitioner
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Disclosures

Disclosure: Virginia Seery, RN, MSN, ANP-BC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Array BioPharma

Ms Seery does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Seery does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Davecia R. Cameron, MS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

CE Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Nurses

Awarded 0.75 contact hour(s) of continuing nursing education for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

The Nurse View: A Clinical Resource for Oncology Nurses

From Medscape Education Oncology

Oncology Nurse View: Immune Checkpoint Inhibitors in Genitourinary Cancers

Authors: Sally Rafikh, RN, BSN, OCN; Pam Profusek, RN, MS; Virginia Seery, RN, MSN, ANP-BCFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CE Released: 6/24/2018

Valid for credit through: 6/24/2019, 11:59 PM EST

processing....

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CE Information Download Slides

Audience Q & A

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

Sally Rafikh, RN, BSN, OCN

Panelists

Pam Profusek, RN, MS

Virginia Seery, RN, MSN, ANP-BC

Editor

Davecia R. Cameron, MS

CE Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC

CE

Oncology Nurse View: Immune Checkpoint Inhibitors in Genitourinary Cancers

Target Audience and Goal Statement

Disclosures

Moderator

Sally Rafikh, RN, BSN, OCN

Panelists

Pam Profusek, RN, MS

Virginia Seery, RN, MSN, ANP-BC

Editor

Davecia R. Cameron, MS

CE Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Accreditation Statements

For Nurses

Instructions for Participation and Credit

Oncology Nurse View: Immune Checkpoint Inhibitors in Genitourinary Cancers

Educational Impact Challenge